Updated recommendations from the American College of Radiology encouraged all women—particularly Black women and Ashkenazi Jewish women—to undergo risk assessments at 25 years of age to determine whether they may need breast cancer screenings earlier than age 40, according to new guidelines published by Monticciolo et al in the Journal of the American College of Radiology.
The American College of Radiology continues to recommend annual breast cancer screenings for average-risk women aged 40 years; however, earlier and more intensive screenings for high-risk patients may be needed.
Research Findings and New Screening Recommendations
Factors that contributed to the reclassification of Black women and other minorities as high risk included that, when compared with non-Hispanic White women:
“The latest scientific evidence continues to point to earlier assessment as well as augmented and earlier-than-age-40 screenings [for] many women—particularly Black women and other minority women,” emphasized lead guideline author Debra Monticciolo, MD, FACR, Chief of the Division of Breast Imaging and Co-Director of the Avon Comprehensive Breast Evaluation Center at Massachusetts General Hospital. “These evidence-based updates should spur more informed doctor-patient conversations and help providers save more lives,” she said.
Among the new breast cancer screening updates were:
“Since 1990, breast cancer death rates in Black women, who develop and die from the disease earlier, have only dropped approximately half as fast as in White women,” stressed senior guideline author Stamatia Destounis, MD, FACR, Chair of the Breast Imaging Commission and the Breast MRI Accreditation Committee at the American College of Radiology and a managing partner at Elizabeth Wende Breast Care. “We continue to regularly examine the latest evidence and update our recommendations to help save more Black women and others at high risk from this deadly disease,” she concluded.
Disclosure: For full disclosures of the guideline authors, visit jacr.org.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.